Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/29 10:00:35 pm
58.66 USD   +0.39%
07/30DJMERCK : Earnings Watch -- WSJ
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29 DOW MOVERS : Xom, mrk
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : WSJ BLOG/Health : Experimental Drug Might Open New Category of Sleep Aid

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 06:17pm CEST

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Christopher Weaver

Patients with severe insomnia taking a Merck experimental sleep drug drifted off faster and slept longer than those taking placebos in two clinical studies discussed at a Boston sleep conference today.

The drug, suvorexant, opens a new category of sleep drugs by blocking orexin, the brain's chemical emissaries that promote alertness. Merck says it plans to apply for FDA approval later this year.

Both of Merck's trials included more than 1,000 patients with insomnia. Patients whose sleep troubles were caused by other medical problems weren't included in the studies. The results were reported after three months of taking the drug or a placebo.

Those taking suvorexant reported falling asleep 25.7 minutes faster than usual, and sleeping an hour longer in one trial. Merck's researchers also observed patients in sleep labs and determined that patients taking the drug fell asleep 36 minutes faster than usual, while those taking placebos fell asleep 26.6 minutes faster.

The second trial also showed the drug helped people sleep longer, though people in that group who took it didn't fall asleep faster than patients taking placebos.

The findings were presented at the Sleep 2012, an annual meeting of sleep scientists and health providers.

The U.S. market for sleep drugs sagged to $1.85 billion in 2011, down about 8% from the prior year, according to IMS Health, a health-care-information company. The decline was driven by generic competition for key sleep drugs.

Suvorexant could offer a new option for patients with chronic insomnia who routinely need sleeping pills, Merck hopes. Other sleep drugs on the market, such as Ambien, keep patients asleep for about two thirds of the night, while suvorexant provides longer rest, Dr. Darryle Schoepp, Merck's vice president in charge of neuroscience, said in an interview last week.

For decades, a series of sleep drugs have focused on "shutting down the whole brain in maybe a less natural way," Schoepp said. So-called Gaba agonists, such as Ambien, Sonata and Lunesta, which are often prescribed to be taken as needed, have been shown to have side effects, including sleep walking, in a small fraction of patients.

Merck says patients who routinely need sleep aids will better tolerate suvorexant, which also performed well in a cohort of patients Merck followed for a full year. In contrast to older drugs, Schoepp said, Merck's research showed that patients taking suvorexant experienced normal sleep rhythm.

The study showed suvorexant's main side effects were headaches and morning drowsiness.

 
 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
07/30DJMERCK : Earnings Watch -- WSJ
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29 DOW MOVERS : Xom, mrk
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/29 MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
07/29 MERCK : European Commission Grants Marketing Authorisation for MSD’s ZEPAT..
07/29 MERCK : beats 2Q profit forecasts
07/29 MERCK : Announces Second-Quarter 2016 Financial Results
07/28 MERCK : Patent Issued for Caspofungin Composition (USPTO 9393307)
More news
Sector news : Pharmaceuticals - NEC
07/30 BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/29 Real Estate Is Bigger Than REITs! Here's More.
07/29 Merck & Co. (MRK) Kenneth C. Frazier on Q2 2016 Results - Earnings Call Trans..
07/29 Big Week Climaxes With A First Look At GDP Along With Pharma, Energy Earnings
07/29 Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance
07/29 Merck beats by $0.02, beats on revenue
Advertisement
Financials ($)
Sales 2016 39 496 M
EBIT 2016 13 520 M
Net income 2016 5 867 M
Debt 2016 4 427 M
Yield 2016 3,15%
P/E ratio 2016 27,66
P/E ratio 2017 19,68
EV / Sales 2016 4,22x
EV / Sales 2017 4,20x
Capitalization 162 372 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 62,1 $
Spread / Average Target 5,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.06%162 372
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-10.46%218 231
NOVARTIS AG-5.30%215 109
BRISTOL-MYERS SQUIBB C..8.75%124 997
More Results